Charcot Marie Tooth Disease Type 1A
C3-PMP22 Mouse Model
Mutations in the PMP22 gene cause several forms of neuropathies such as Charcot-Marie-Tooth Disease Type 1A
Charcot Marie Tooth Disease Type 1A (CMT1A) is a hereditary, demyelinating peripheral neuropathy, leading to progressive skeletal muscle atrophy, weakenss and subsequent walking diabilities and sensory impairments. This autosomal, dominantly inherited disease is caused by a duplication of a segment on chromosome 17p11.2 containing the gene encoding peripheral myelin protein 22 (PMP22).
To help accelerate CMT1A research to clinic, InnoSer offers specialized preclinical research services using the C3-PMP22 mouse model (Verhamme et al. 2011) of CMT1A. Transgenic C3-PMP22 mice carry multiple copies of the wild-type human PMP22 gene. The C3-PMP22 mouse model shows a mild disease phenotype that more closely resembles the human disease pathophysiology. As part of our services, InnoSer offers you with efficacy studies in the C3-PMP22 mouse model of CMT1A, focusing on functional readouts such as sciatic nerve conduction electrophysiology and motor function assessments, as well as histopathology analyses.
InnoSer’s scientists have extensive experience in performing efficacy studies in the C3-PMP22 mouse model of CMT1A and have published numerous papers using this mouse model (Michailidou et al. 2023 and Prior et al. 2024).
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, and gene therapy (viral vectors – e.g.. AAVs).
C3-PMP22 model key characteristics:
- The C3-PMP22 mouse model reverts back to the original C22-PMP22 model on its own after being bred with C57BL/6J mice.
- Model contains 3 to 4 copies of the human PMP22 gene.
- In comparison to the original C22-PMP22 model, the C3-PMP22 model shows a milder disease phenotype, better resembling the human disease course of CMT1A.
- Model is extensively characterised (findings published together with Michailidou et al. 2023).
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Key readouts in the C3-PMP22 mouse model
Test the efficacy of your treatments in the following battery of behavioural tests:
- Spontaneous behaviour (automatic home-cages)
- CatWalk: Automated Gait Analysis
- Balance Beam
- Grip Strength Test
Neuromuscular function
- Compound muscle action potential (CMAP)
- Sensory nerve conduction velocity (SNCV)
- Sciatic nerve histology
Example data featuring the C3-PMP22 mouse model
C3-PMP22 mice have reduced motor function, as indicated by a higher number of slips on the balance beam
The Balance Beam sensorimotor coordination test scores the ability of mice to traverse a stationary horizontal rod. The coordination of the mouse is measured by the latency to cross the beam and the number of foot slips made.
Sciatic nerve conduction recording in C3-PMP22 mice
Compared to WT mice, C3-PMP22 mutant mice (9 weeks of age) show significantly prolonged nerve conduction velocity latencies, as well as a significant reduction in CMAP amplitude recordings.
Compared to WT mice, C3PMP22 mice (15 -week-old) show deficits in motor function
The Rotarod is the golden standard for assessing motor performance and learning in mice. The mice are placed on a rotating rod, with increasing rotating speed. Motor performance is measured by the maximal RPM (rounds per minute) at which mice are able to keep up with the rotating rod. Motor learning can be assessed by training mice on the rod for several trials.
Related rare disease mouse model options
Infantile Epileptic Encephalopathy – Stxbp1 Mouse Model
InnoSer offers services using a unique Stxbp1 +/- mouse model.
Fragile X Syndrome – Fmr1 KO Mouse Model
InnoSer offers unique preclinical behavioural research studies using Fmr1 knock-out (KO) mouse model.
Vanishing White Matter (eIF2B) Mouse Models
InnoSer offers unique services with an Eif2b4 / Eif2b5 mouse model of vanishing white matter (VWM).
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
References
- Michailidou I, Vreijling J, Rumpf M, Loos M, Koopmans B, Vlek N, Straat N, Agaser C, Kuipers TB, Mei H, Baas F. The systemic inhibition of the terminal complement system reduces neuroinflammation but does not improve motor function in mouse models of CMT1A with overexpressed PMP22. Current Research in Neurobiology. 2023 Jan 1;4:100077.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know